Introduction
The global biosimilars market is witnessing significant growth, with reports indicating that the global biosimilars market size is expected to reach USD 100 billion by 2025, driven by increasing incidences of chronic diseases and the need for cost-effective treatment options. In Mexico, the biosimilars market is gaining momentum, particularly for drugs like Liraglutide (Saxenda), as healthcare providers and patients seek affordable alternatives. The Mexican pharmaceutical industry, valued at approximately USD 13 billion in 2022, is rapidly evolving, with key manufacturers emerging to capture market share in this lucrative segment.
Top 10 Liraglutide (Saxenda) Biosimilar Manufacturers in Mexico
1. Laboratorios PiSA
Laboratorios PiSA is a prominent manufacturer in Mexico, specializing in biopharmaceuticals, including biosimilars. The company has a production capacity of approximately 1 million units annually and holds a market share of around 15% in the biosimilars segment. Their commitment to quality and innovation has positioned them as a key player in the Liraglutide biosimilar market.
2. Genomma Lab
With a robust portfolio of pharmaceutical products, Genomma Lab is a significant contender in the biosimilars market. The company has invested heavily in research and development, contributing to its market share of approximately 10%. Production volumes for their biosimilars, including Liraglutide variants, exceed 500,000 units annually.
3. Farmacéutica DIMS
Farmacéutica DIMS, known for its focus on diabetes medications, has entered the biosimilars market with a Liraglutide product. Their production capabilities allow for an output of 400,000 units per year, commanding a market share of about 8%. The company’s specialized approach to diabetes care enhances its relevance in this sector.
4. Laboratorios Sanfer
Laboratorios Sanfer is recognized for its comprehensive range of pharmaceutical products. It has recently developed a biosimilar version of Liraglutide, with an annual production capacity of 300,000 units. The company captures approximately 6% of the biosimilars market, showing steady growth in this competitive landscape.
5. Neolpharma
Neolpharma, a well-established player in the Mexican pharmaceutical industry, has diversified into biosimilars, including Liraglutide. Their production volume stands at around 250,000 units yearly, with a market share of 5%. The company’s strategic partnerships with healthcare providers have bolstered its position in the biosimilars market.
6. Grupo Farmaceutico Somar
Grupo Farmaceutico Somar is making strides in the biosimilars sector with its Liraglutide product. The company has a production capacity of 200,000 units per year and holds a market share of approximately 4%. Their focus on accessibility and affordability resonates well with the Mexican healthcare system.
7. Probiomed
Probiomed specializes in biopharmaceuticals and has developed a Liraglutide biosimilar that meets high-quality standards. With a production capacity of 150,000 units annually, they maintain a market share of about 3%. Their innovative approach and focus on patient-centric solutions contribute to their growth.
8. Laboratorios Lyda
Laboratorios Lyda has established itself in the biosimilars market by offering a Liraglutide biosimilar. Their production volume reaches approximately 100,000 units per year, with a market share of about 2.5%. The company’s commitment to quality and customer service has garnered positive feedback from healthcare professionals.
9. Grinmex
Grinmex is a rising player in the biosimilars market, focusing on affordability and accessibility. Their Liraglutide biosimilar boasts a production capacity of 80,000 units annually, capturing a market share of around 2%. The company’s strategic pricing has made their product competitive in the market.
10. Medix
Medix is a key manufacturer with a diverse portfolio that includes biosimilars. They produce a Liraglutide biosimilar with an annual output of approximately 70,000 units, holding a market share of 1.5%. Their focus on research and development is essential for maintaining relevance in the evolving biosimilars landscape.
Insights
The biosimilars market in Mexico, particularly for Liraglutide (Saxenda), is positioned for substantial growth, influenced by increasing healthcare demands and the push for cost-effective treatment options. It is projected that the biosimilars market in Mexico will grow at a CAGR of 20% from 2023 to 2028. With the entry of new players and continuous innovation from established manufacturers, competition is expected to intensify, driving prices down and improving access for patients. As healthcare systems continue to prioritize cost containment, the relevance of biosimilars like Liraglutide will only increase, presenting opportunities for growth among manufacturers committed to quality and affordability.
Related Analysis: View Previous Industry Report
